Praxis Precision Medicines Inc is a biopharmaceutical company focused on developing treatments for central nervous system disorders. It works on innovative therapies targeting conditions caused by an imbalance in neuronal excitation and inhibition. Key projects include ulixacaltamide for essential tremor and Parkinson’s disease, and several other compounds aimed at treating various epilepsies and developmental disorders. Founded in 2015 and headquartered in Boston, Massachusetts, Praxis collaborates with notable institutions like Ionis Pharmaceuticals and The Florey Institute to advance its research.
Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower…
Pre-Market Stock Futures: Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses. The Dow Jones Industrials closed…
